
USD
+$0.00
(+0.00%
)At Close (As of Nov 26, 2025)
$142.03M
Market Cap
-
P/E Ratio
-2.22
EPS
$4.98
52 Week High
$1.15
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$1.1M |
| Total Revenue | $0 |
| Cost Of Revenue | $1.1M |
| Costof Goods And Services Sold | $1.1M |
| Operating Income | -$141M |
| Selling General And Administrative | $72M |
| Research And Development | $70M |
| Operating Expenses | $141M |
| Investment Income Net | - |
| Net Interest Income | $8.5M |
| Interest Income | $8.5M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.1M |
| Income Before Tax | -$24M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$142M |
| Ebitda | -$141M |
| Net Income | -$24M |
| Field | Value (USD) |
|---|---|
| Total Assets | $158M |
| Total Current Assets | $137M |
| Cash And Cash Equivalents At Carrying Value | $129M |
| Cash And Short Term Investments | $129M |
| Inventory | - |
| Current Net Receivables | $947K |
| Total Non Current Assets | $21M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $37K |
| Intangible Assets Excluding Goodwill | $37K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $7M |
| Other Non Current Assets | - |
| Total Liabilities | $12M |
| Total Current Liabilities | $12M |
| Current Accounts Payable | $7.7M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | - |
| Total Non Current Liabilities | $79K |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | - |
| Other Current Liabilities | $4.1M |
| Other Non Current Liabilities | $79K |
| Total Shareholder Equity | $146M |
| Treasury Stock | - |
| Retained Earnings | -$405M |
| Common Stock | $48K |
| Common Stock Shares Outstanding | $47M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$117M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $1.1M |
| Capital Expenditures | $103K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$103K |
| Cashflow From Financing | $124M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$24M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$1.1M |
| Total Revenue | $0 |
| Cost Of Revenue | $1.1M |
| Costof Goods And Services Sold | $1.1M |
| Operating Income | -$141M |
| Selling General And Administrative | $72M |
| Research And Development | $70M |
| Operating Expenses | $141M |
| Investment Income Net | - |
| Net Interest Income | $8.5M |
| Interest Income | $8.5M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $1.1M |
| Income Before Tax | -$24M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$142M |
| Ebitda | -$141M |
| Net Income | -$24M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2012-12-13 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 0.75 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Cassava Sciences, Inc. is a clinical-stage biotechnology firm headquartered in Austin, Texas, focused on developing breakthrough therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its leading candidate, simufilam, is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. By targeting significant unmet medical needs in neurology, Cassava aims to revolutionize the treatment paradigm for neurodegenerative disorders, setting a foundation for improving patient outcomes and quality of life while enhancing its strategic position within the biotechnology sector.